As of its fiscal quarter ending in June 2024, Dr. Reddy's Laboratories reported INR 30.68 billion in debt.
Dr. Reddy's Debt Overview
Dr. Reddy's Laboratories, a prominent pharmaceutical company, reported a specific debt figure for its most recent fiscal quarter. This amount, INR 30.68 billion, represents the company's total financial obligations as of June 2024. The term "INR" stands for Indian Rupees, indicating the currency in which the debt is denominated.
Understanding a company's debt is crucial for assessing its financial health and leverage. Debt can be used for various purposes, such as funding operations, capital expenditures, or acquisitions. The reported figure reflects the total liabilities owed by the company at that specific point in time.
Comparative Debt Analysis
To provide a broader context, Dr. Reddy's Laboratories' debt can be compared with that of other major companies. The table below illustrates the debt figures for select companies, including Dr. Reddy's, as reported for their respective fiscal periods:
| Company | Debt (INR) | Change (INR) |
|---|---|---|
| Cipla | 4.61 Billion | 980.3 Million |
| Dr. Reddy's Laboratories | 30.68 Billion | 10.66 Billion |
| Sun Pharmaceuticals | 25.72 Billion | 7.02 Billion |
| UPL | 332.17 Billion | 34.63 Billion |
This comparison helps in understanding Dr. Reddy's debt position relative to its peers and other large entities, indicating its financial scale and operational funding strategies within the market.
